A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma

Meser M. Ali, Mohammed P.I. Bhuiyan, Branislava Janic, Nadimpalli R.S. Varma, Tom Mikkelsen, James R. Ewing, Robert A. Knight, Mark D. Pagel, Ali S. Arbab

Research output: Contribution to journalArticlepeer-review

31 Scopus citations

Abstract

Aim: The authors have investigated the usefulness of in vivo chemical exchange saturation transfer MRI for detecting gliomas using a dual-modality imaging contrast agent. Materials & methods: A paramagnetic chemical exchange saturation transfer MRI contrast agent, Eu-1,4,7,10- tetraazacclododecane-1,4,7,10-tetraacetic acid-Gly4 and a fluorescent agent, DyLight® 680, were conjugated to a generation 5 polyamidoamine dendrimer to create the dual-modality, nano-sized imaging contrast agent. Results: The agent was detected with in vivo chemical exchange saturation transfer MRI in an U87 glioma model. These results were validated using in vivo and ex vivo fluorescence imaging. Conclusion: This study demonstrated the merits of using a nano-sized imaging contrast agent for detecting gliomas and using a dual-modality agent for detecting gliomas at different spatial scales. Original submitted 9 January 2012; Revised submitted 18 April 2012; Published online 14 August 201.

Original languageEnglish (US)
Pages (from-to)1827-1837
Number of pages11
JournalNanomedicine
Volume7
Issue number12
DOIs
StatePublished - Dec 2012
Externally publishedYes

Keywords

  • MRI
  • brain tumor
  • contrast agent
  • dendrimer
  • pharmacokinetic

ASJC Scopus subject areas

  • Bioengineering
  • Medicine (miscellaneous)
  • Biomedical Engineering
  • General Materials Science

Fingerprint

Dive into the research topics of 'A nano-sized PARACEST-fluorescence imaging contrast agent facilitates and validates in vivo CEST MRI detection of glioma'. Together they form a unique fingerprint.

Cite this